171 related articles for article (PubMed ID: 17369602)
1. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.
Di Leo A; Tanner M; Desmedt C; Paesmans M; Cardoso F; Durbecq V; Chan S; Perren T; Aapro M; Sotiriou C; Piccart MJ; Larsimont D; Isola J;
Ann Oncol; 2007 Jun; 18(6):997-1003. PubMed ID: 17369602
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
Durbecq V; Paesmans M; Cardoso F; Desmedt C; Di Leo A; Chan S; Friedrichs K; Pinter T; Van Belle S; Murray E; Bodrogi I; Walpole E; Lesperance B; Korec S; Crown J; Simmonds P; Perren TJ; Leroy JY; Rouas G; Sotiriou C; Piccart M; Larsimont D
Mol Cancer Ther; 2004 Oct; 3(10):1207-14. PubMed ID: 15486187
[TBL] [Abstract][Full Text] [Related]
3. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
Di Leo A; Chan S; Paesmans M; Friedrichs K; Pinter T; Cocquyt V; Murray E; Bodrogi I; Walpole E; Lesperance B; Korec S; Crown J; Simmonds P; Von Minckwitz G; Leroy JY; Durbecq V; Isola J; Aapro M; Piccart MJ; Larsimont D
Breast Cancer Res Treat; 2004 Aug; 86(3):197-206. PubMed ID: 15567936
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
Fernández-Cuesta L; Oakman C; Falagan-Lotsch P; Smoth KS; Quinaux E; Buyse M; Dolci MS; Azambuja ED; Hainaut P; Dell'orto P; Larsimont D; Francis PA; Crown J; Piccart-Gebhart M; Viale G; Leo AD; Olivier M
Breast Cancer Res; 2012 May; 14(3):R70. PubMed ID: 22551440
[TBL] [Abstract][Full Text] [Related]
5. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
Galmarini CM; Treilleux I; Cardoso F; Bernard-Marty C; Durbecq V; Gancberg D; Bissery MC; Paesmans M; Larsimont D; Piccart MJ; Di Leo A; Dumontet C
Clin Cancer Res; 2008 Jul; 14(14):4511-6. PubMed ID: 18628466
[TBL] [Abstract][Full Text] [Related]
6. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
Ooe A; Kato K; Noguchi S
Breast Cancer Res Treat; 2007 Mar; 101(3):305-15. PubMed ID: 16821082
[TBL] [Abstract][Full Text] [Related]
7. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
[TBL] [Abstract][Full Text] [Related]
8. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.
Sonnenblick A; Francis PA; Azim HA; de Azambuja E; Nordenskjöld B; Gutiérez J; Quinaux E; Mastropasqua MG; Ameye L; Anderson M; Lluch A; Gnant M; Goldhirsch A; Di Leo A; Barnadas A; Cortes-Funes H; Piccart M; Crown J
Eur J Cancer; 2015 Aug; 51(12):1481-9. PubMed ID: 26074397
[TBL] [Abstract][Full Text] [Related]
9. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
Cardoso F; Durbecq V; Larsimont D; Paesmans M; Leroy JY; Rouas G; Sotiriou C; Renard N; Richard V; Piccart MJ; Di Leo A
Int J Oncol; 2004 Jan; 24(1):201-9. PubMed ID: 14654958
[TBL] [Abstract][Full Text] [Related]
10. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
Martin M; Romero A; Cheang MC; López García-Asenjo JA; García-Saenz JA; Oliva B; Román JM; He X; Casado A; de la Torre J; Furio V; Puente J; Caldés T; Vidart JA; Lopez-Tarruella S; Diaz-Rubio E; Perou CM
Breast Cancer Res Treat; 2011 Jul; 128(1):127-36. PubMed ID: 21465170
[TBL] [Abstract][Full Text] [Related]
11. Single-agent docetaxel (Taxotere) in randomized phase III trials.
Burris HA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
Rody A; Karn T; Gätje R; Ahr A; Solbach C; Kourtis K; Munnes M; Loibl S; Kissler S; Ruckhäberle E; Holtrich U; von Minckwitz G; Kaufmann M
Breast; 2007 Feb; 16(1):86-93. PubMed ID: 17010609
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?
Di Leo A; Isola J
Clin Breast Cancer; 2003 Aug; 4(3):179-86. PubMed ID: 14499010
[TBL] [Abstract][Full Text] [Related]
15. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial.
Ruiz-Pinto S; Martin M; Pita G; Caronia D; de la Torre-Montero JC; Moreno LT; Moreno F; García-Sáenz JÁ; Benítez J; González-Neira A
Pharmacogenet Genomics; 2018 Nov; 28(11):245-250. PubMed ID: 30334909
[TBL] [Abstract][Full Text] [Related]
17. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
Aapro M
Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
Heery CR; Ibrahim NK; Arlen PM; Mohebtash M; Murray JL; Koenig K; Madan RA; McMahon S; Marté JL; Steinberg SM; Donahue RN; Grenga I; Jochems C; Farsaci B; Folio LR; Schlom J; Gulley JL
JAMA Oncol; 2015 Nov; 1(8):1087-95. PubMed ID: 26291768
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Nabholtz JM
Semin Oncol; 1999 Jun; 26(3 Suppl 9):7-13. PubMed ID: 10426453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]